A major clinical advantage of these agents is afforded by the ability to individualise the dose of β−-particle radiation therapy by first measuring the tumour burden using an imaging agent containing the same targeting vector as the therapeutic agent (e.g., octreotate, which targets somatostatin receptors in NET; or vipivotide tetraxetan (PSMA-617), which targets prostate-specific membrane antigen (PSMA) in mCRPC). The gene discussed is FOLH1; the disease is neoplasm.